IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
Arthritis Care Res (Hoboken). 2010 Feb;62(2):219-25. doi: 10.1002/acr.20071.
To use juvenile dermatomyositis (DM) survey data and expert opinion to develop a small number of consensus treatment protocols, which reflect current initial treatment of moderately severe juvenile DM.
A consensus meeting was held in Toronto, Ontario, Canada on December 1-2, 2007. Nominal group technique was used to achieve consensus on treatment protocols, which represented typical management of moderately severe juvenile DM. Consensus was also reached as to which patients these protocols would be applicable (inclusion and exclusion criteria), which initial investigations should be done prior to initiating one of these protocols, which data should be collected to evaluate these protocols, and the concomitant interventions required or recommended.
Three protocols that described the first 2 months of treatment were developed. All protocols included corticosteroids and methotrexate. One protocol also included intravenous gamma globulin. Consensus was achieved for all issues that were addressed by conference participants, although there were some areas of controversy.
Despite considerable variation in clinical practice, it is possible to achieve consensus on the initial treatment of juvenile DM. Once these protocols are extended beyond 2 months, these protocols will be available for clinical use. By using methods that account for differences between patients (confounding by indication), the comparative effectiveness of the protocols will be evaluated. In the future, the goal will be to identify the optimal treatment of moderately severe juvenile DM.
利用幼年皮肌炎(DM)调查数据和专家意见,制定少量共识治疗方案,反映当前中度严重幼年 DM 的初始治疗。
2007 年 12 月 1 日至 2 日,在加拿大安大略省多伦多举行了共识会议。名义小组技术用于就治疗方案达成共识,这些方案代表了中度严重幼年 DM 的典型治疗。还就这些方案适用的患者达成了共识(纳入和排除标准),在开始这些方案之一之前应进行哪些初步检查,应收集哪些数据来评估这些方案,以及需要或建议哪些伴随干预措施。
制定了三个描述前 2 个月治疗的方案。所有方案均包括皮质类固醇和甲氨蝶呤。一个方案还包括静脉注射丙种球蛋白。尽管存在一些争议,但会议参与者提出的所有问题都达成了共识。
尽管临床实践存在很大差异,但仍有可能就幼年 DM 的初始治疗达成共识。一旦这些方案延长至 2 个月以上,这些方案将可供临床使用。通过使用考虑到患者差异的方法(指示性混杂),将评估方案的比较效果。未来的目标将是确定中度严重幼年 DM 的最佳治疗方法。